Brief: Novartis CFO Says Companies That Signed US Deals Will Have To Be Very Cautious Around Pricing Of Drug Launches In MFN Countries
28/04/2026 08:35
April 28 (Reuters) - NOVARTIS AG NOVN.S: NOVARTIS CFO SAYS ON U.S. PATENT EXPIRATIONS: Q2 IMPACT FOR ENTRESTO WILL BE SIMILAR TO Q1, STARTING Q3 IMPACT WILL BE A LOT LESS -INTERVIEW NOVARTIS CFO SAYS ALL 17 COMPANIES THAT SIGNED U.S. DEALS WILL HAVE TO BE VERY CAUTIOUS AROUND PRICING OF DRUG LAUNCHES IN MFN COUNTRIES NOVARTIS CFO SAYS IF MFN POLICY IS CODIFIED INTO LAW, IT WOULD BE ONE SIDED NOVARTIS CFO SAYS NO PLANS TO CHANGE CO'S QUARTERLY REPORTING CYCLE Further company coverage: NOVN.S
Recent news on Novartis AG
See all newsBrief: Novartis Remind Data At Eaaci Show Rhapsido Potential As First Targeted Therapy For Chronic Inducible Urticaria (Cindu)
Swiss stocks - Factors to watch on June 12
Swiss pharma hub Basel frets over population cap threat
Novartis says rare muscle disease drug shows promise in early trial
Live Markets: Europe at half-time: countdown to the ECB's 'insurance hike'